EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Phase 3
Completed
- Conditions
- Generalized Anxiety Disorder (GAD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Edgemont Pharmaceuticals, LLC
- Target Recruit Count
- 495
- Registration Number
- NCT02305797
- Locations
- 🇺🇸
Multiple Investigational Sites, Multiple Locations, California, United States
© Copyright 2025. All Rights Reserved by MedPath